Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 5/20 | 0.41 |
| ▸ | PIK3C3 | Q8NEB9 | 7/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.38 |
| ▸ | TGFBR2 | P37173 | 3/20 | 0.38 |
| ▸ | EIF4E | P06730 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | CDC7 | O00311 | 1/20 | 0.36 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16938042 | 0.89 | GSK3B (0.42) | GSK3BPIK3C3MAPK14TGFBR1TGFBR2 | |
| SCHEMBL6842878 | 0.86 | MAPK14 (0.49) | GSK3BPIK3C3MAPK14CDC7DBF4 | |
| SCHEMBL13257577 | 0.84 | DYRK1A (0.38) | GSK3BMAPK14EIF4ECDC7DBF4 | |
| SCHEMBL953124 | 0.84 | MAPK14 (0.47) | PIK3C3MAPK14 | |
| SCHEMBL12947666 | 0.83 | PIK3C3 (0.44) | GSK3BPIK3C3MAPK14TGFBR1CDC7 | |
| SCHEMBL954822 | 0.81 | MAPK14 (0.45) | GSK3BPIK3C3MAPK14TGFBR1TGFBR2 | |
| SCHEMBL6842867 | 0.81 | CDC7 (0.42) | GSK3BPIK3C3MAPK14TGFBR1TGFBR2 | |
| SCHEMBL16938040 | 0.81 | MAPK14 (0.43) | GSK3BPIK3C3MAPK14CDC7DBF4 | |
| SCHEMBL953912 | 0.79 | MAPK14 (0.42) | GSK3BPIK3C3MAPK14CDC7DBF4 | |
| SCHEMBL16850488 | 0.76 | GSK3B (0.44) | GSK3BPIK3C3MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9139589-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9139589-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9090601-B2 | Thiazole derivatives | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-9090601-B2 | Thiazole derivatives | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-20110003807-A1 | Thiazole derivatives | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-20110003807-A1 | Thiazole derivatives | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-20110003806-A1 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-20110003806-A1 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003807-A1 | Thiazole derivatives | MTOR, RICTOR, AKT2 | GSK3B 62/4885PIK3C3 15/4885MAPK14 102/4885 |
| US-20110003806-A1 | Heteroaryls and uses thereof | RICTOR, MTOR, AKT1S1 | GSK3B 80/4885PIK3C3 61/4885MAPK14 899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.